REGENT PACIFIC: Jiangsu Wanbang Pharmaceutical is advancing the new drug application for SenstendTM with the National Medical Products Administration of China

According to the Zhitong Finance APP, REGENT PACIFIC (00575) announced that its commercial strategic partner Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd. (Jiangsu Wanbang Pharmaceutical, a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.) is advancing the new drug application for SenstendTM with the National Medical Products Administration (NMPA) of China. In this regard, Jiangsu Wanbang Pharmaceutical has received the first round of inquiries from the NMPA regarding the new drug application documents and has submitted a comprehensive response in a timely manner. To support the new drug application, Jiangsu Wanbang Pharmaceutical has submitted 900 commercial samples of SenstendTM produced by its manufacturing partners to the Drug Evaluation Center. Jiangsu Wanbang Pharmaceutical remains optimistic about obtaining new drug application approval by the end of 2025 and starting the first commercial launch in the first quarter of 2026. Deep Longevity Makes Positive Progress Deep Longevity, Inc (a wholly-owned subsidiary of the company, Deep Longevity) has continued to make progress in expanding its new customer base in the first half of this year, with notable new clients including Ren Shan Medical in Hong Kong (https://www.humansahealth.com) and Holistica World in India (https://www.holisticaworld.com). Additionally, compared to the same period last year, the usage of Deep Longevity's aging clock by clients has increased in the first half of this year, demonstrating the value of the technology and the growing attention to longevity and health as a health trend. Deep Longevity aims to establish new partnerships with longevity applications adopting a B2C model, other platforms, startups, and diagnostic companies. Deep Longevity is committed to launching its aging clock in the largest longevity market, the United States, and has appointed a U.S. president to lead market expansion efforts, which is expected to drive business growth. Notably, while the longevity and health market is still in its early development stages, this unique technology aims to enter this vast and continuously growing market, estimated to be worth over $63 trillion in 2023. Deep Longevity has active channels and is currently engaged in extensive discussions with several longevity clinics and other companies interested in using the aging clock in markets such as Brazil, Germany, and Southeast Asia. Deep Longevity has also updated its aging clock with a Biometric Age feature, providing clients with additional measurements using 17 blood biomarkers and 4 biometrics (including blood pressure and waist circumference). Furthermore, Deep Longevity continues to update its large language model to provide more accurate Blood Age and Mind Age reports Deep Longevity is conducting further research and development to add a new clock to its product line, namely "Face Age" or "Face Index Score." In addition, Deep Longevity is exploring the addition of other new clocks focused on health, beauty, and wellness to its existing product line